ONCOGENEX PHARMACEUTICALS IN's ticker is OGXI and the CUSIP is 68230A106. A total of 55 filers reported holding ONCOGENEX PHARMACEUTICALS IN in Q4 2015. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2017 | $212,000 | -28.6% | 588,568 | -12.7% | 0.00% | – |
Q1 2017 | $297,000 | -11.6% | 674,078 | +0.4% | 0.00% | – |
Q4 2016 | $336,000 | -14.1% | 671,278 | -12.9% | 0.00% | – |
Q3 2016 | $391,000 | -53.5% | 770,960 | -8.3% | 0.00% | – |
Q2 2016 | $841,000 | +46.3% | 840,744 | 0.0% | 0.00% | – |
Q1 2016 | $575,000 | -37.5% | 840,744 | +10.6% | 0.00% | – |
Q4 2015 | $920,000 | -45.6% | 760,278 | +0.1% | 0.00% | – |
Q3 2015 | $1,692,000 | +47.3% | 759,145 | +53.8% | 0.00% | – |
Q2 2015 | $1,149,000 | +14.8% | 493,469 | +6.0% | 0.00% | – |
Q1 2015 | $1,001,000 | +4.3% | 465,498 | +11.0% | 0.00% | – |
Q4 2014 | $960,000 | -11.1% | 419,357 | +3.7% | 0.00% | – |
Q3 2014 | $1,080,000 | -15.0% | 404,585 | +18.9% | 0.00% | – |
Q2 2014 | $1,270,000 | -66.8% | 340,393 | +4.6% | 0.00% | – |
Q1 2014 | $3,827,000 | +115.5% | 325,397 | +52.8% | 0.00% | – |
Q4 2013 | $1,776,000 | -30.4% | 212,992 | -22.6% | 0.00% | – |
Q3 2013 | $2,550,000 | -5.6% | 275,148 | -0.2% | 0.00% | – |
Q2 2013 | $2,702,000 | – | 275,700 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Abingworth LLP | 396,104 | $400,000 | 0.42% |
Ancora Advisors LLC | 50,865 | $51,000 | 0.01% |
EAGLE GLOBAL ADVISORS LLC | 145,710 | $146,000 | 0.00% |
Acrospire Investment Management LLC | 5,200 | $5,000 | 0.00% |
A.R.T. Advisors, LLC | 57,954 | $57,000 | 0.00% |
Renaissance Technologies | 876,100 | $876,000 | 0.00% |
PRELUDE CAPITAL MANAGEMENT, LLC | 4,600 | $5,000 | 0.00% |
Cutler Group LLC / CA | 11,048 | $11,000 | 0.00% |
PANAGORA ASSET MANAGEMENT INC | 133,846 | $134,000 | 0.00% |
PRICE T ROWE ASSOCIATES INC /MD/ | 46,100 | $46,000 | 0.00% |